$74.46
1.652.27%
Pre-Market: 7:41 AM EDT
15 minutes delayed
Comments
Loading...
Globus Medical
GMEDNYSE
want to know what
the Bulls & Bears Say?
Globus Medical (NYSE:GMED) Stock, Analyst Ratings, Price Targets, Forecasts
Globus Medical Inc has a consensus price target of $76.47 based on the ratings of 21 analysts. The high is $96 issued by SVB Leerink on August 5, 2021. The low is $58 issued by Wells Fargo on September 15, 2023. The 3 most-recent analyst ratings were released by Truist Securities, BTIG, and Morgan Stanley on July 16, 2024, July 15, 2024, and July 15, 2024, respectively. With an average price target of $74.67 between Truist Securities, BTIG, and Morgan Stanley, there's an implied 0.28% upside for Globus Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
BTIG
Morgan Stanley
Piper Sandler
Barclays
1calculated from analyst ratings
Analyst Ratings for Globus Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 4.75% | Truist Securities | Richard Newitter | $63 → $78 | Maintains | Hold | Get Alert |
| 07/15/2024 | Buy Now | 0.73% | BTIG | Ryan Zimmerman | $72 → $75 | Maintains | Buy | Get Alert |
| 07/15/2024 | Buy Now | -4.65% | Morgan Stanley | Drew Ranieri | $67 → $71 | Maintains | Equal-Weight | Get Alert |
| 05/29/2024 | Buy Now | -3.3% | BTIG | Ryan Zimmerman | $63 → $72 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 7.44% | Piper Sandler | Matt O'Brien | $60 → $80 | Upgrade | Neutral → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 14.16% | Barclays | Matt Miksic | $83 → $85 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | -15.39% | BTIG | Ryan Zimmerman | $60 → $63 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | -19.42% | Piper Sandler | Matt O'Brien | $55 → $60 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | -5.99% | Stifel | Mathew Blackman | $64 → $70 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | David Saxon | — | Reiterates | → Hold | Get Alert |
| 03/18/2024 | Buy Now | -19.42% | BTIG | Ryan Zimmerman | → $60 | Upgrade | Neutral → Buy | Get Alert |
| 02/21/2024 | Buy Now | -14.05% | Stifel | Mathew Blackman | $61 → $64 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | -19.42% | Truist Securities | Richard Newitter | $58 → $60 | Maintains | Hold | Get Alert |
| 01/11/2024 | Buy Now | -5.99% | RBC Capital | Shagun Singh | → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 12/22/2023 | Buy Now | -22.11% | Truist Securities | Richard Newitter | $53 → $58 | Maintains | Hold | Get Alert |
| 12/20/2023 | Buy Now | -4.65% | Canaccord Genuity | Kyle Rose | $67 → $71 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | -28.82% | Morgan Stanley | Drew Ranieri | $60 → $53 | Maintains | Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | -28.82% | Truist Securities | Richard Newitter | $58 → $53 | Maintains | Hold | Get Alert |
| 10/20/2023 | Buy Now | 0.73% | Roth MKM | Jason Wittes | → $75 | Initiates | → Buy | Get Alert |
| 10/12/2023 | Buy Now | 15.5% | Barclays | Matt Miksic | $77 → $86 | Maintains | Overweight | Get Alert |
| 09/19/2023 | Buy Now | -18.08% | Stifel | Mathew Blackman | → $61 | Upgrade | Hold → Buy | Get Alert |
| 09/15/2023 | Buy Now | -22.11% | Wells Fargo | Vik Chopra | $63 → $58 | Maintains | Equal-Weight | Get Alert |
| 09/05/2023 | Buy Now | -12.7% | Truist Securities | Richard Newitter | → $65 | Reiterates | Hold → Hold | Get Alert |
| 08/07/2023 | Buy Now | -12.7% | Truist Securities | Richard Newitter | $68 → $65 | Maintains | Hold | Get Alert |
| 08/07/2023 | Buy Now | 3.41% | Barclays | Matt Miksic | $75 → $77 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -15.39% | Wells Fargo | Vik Chopra | $61 → $63 | Maintains | Equal-Weight | Get Alert |
| 07/19/2023 | Buy Now | -8.68% | Truist Securities | Richard Newitter | $64 → $68 | Maintains | Hold | Get Alert |
| 05/31/2023 | Buy Now | -19.42% | Morgan Stanley | Drew Ranieri | $64 → $60 | Maintains | Equal-Weight | Get Alert |
| 05/24/2023 | Buy Now | — | JMP Securities | David Turkaly | — | Reiterates | → Market Perform | Get Alert |
| 05/05/2023 | Buy Now | -14.05% | Truist Securities | Richard Newitter | $66 → $64 | Maintains | Hold | Get Alert |
| 03/30/2023 | Buy Now | -10.02% | Canaccord Genuity | Kyle Rose | → $67 | Upgrade | Hold → Buy | Get Alert |
| 03/28/2023 | Buy Now | -10.02% | Canaccord Genuity | Kyle Rose | → $67 | Reiterates | → Hold | Get Alert |
| 02/22/2023 | Buy Now | -14.05% | Morgan Stanley | Drew Ranieri | $78 → $64 | Maintains | Equal-Weight | Get Alert |
| 02/22/2023 | Buy Now | -10.02% | Canaccord Genuity | Kyle Rose | $75 → $67 | Maintains | Hold | Get Alert |
| 02/22/2023 | Buy Now | -18.08% | Wells Fargo | Vik Chopra | $67 → $61 | Maintains | Equal-Weight | Get Alert |
| 02/13/2023 | Buy Now | -15.39% | B of A Securities | Craig Bijou | $83 → $63 | Downgrade | Buy → Underperform | Get Alert |
| 02/10/2023 | Buy Now | -10.02% | Wells Fargo | Vik Chopra | $82 → $67 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/10/2023 | Buy Now | -5.99% | Truist Securities | Richard Newitter | → $70 | Downgrade | Buy → Hold | Get Alert |
| 02/10/2023 | Buy Now | -5.99% | Loop Capital | Jason Wittes | $90 → $70 | Downgrade | Buy → Hold | Get Alert |
| 02/10/2023 | Buy Now | — | Needham | David Saxon | — | Downgrade | Buy → Hold | Get Alert |
| 02/10/2023 | Buy Now | — | BTIG | Ryan Zimmerman | — | Downgrade | Buy → Neutral | Get Alert |
| 02/09/2023 | Buy Now | — | Piper Sandler | Matt O'Brien | — | Downgrade | Overweight → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 4.75% | Morgan Stanley | Drew Ranieri | $68 → $78 | Maintains | Equal-Weight | Get Alert |
| 12/20/2022 | Buy Now | 14.16% | Truist Securities | Richard Newitter | $74 → $85 | Maintains | Buy | Get Alert |
| 12/12/2022 | Buy Now | 10.13% | Wells Fargo | Vik Chopra | $74 → $82 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | -8.68% | Morgan Stanley | Drew Ranieri | $66 → $68 | Maintains | Equal-Weight | Get Alert |
| 10/18/2022 | Buy Now | -7.33% | Barclays | Matt Miksic | → $69 | Initiates | → Overweight | Get Alert |
| 10/12/2022 | Buy Now | 0.73% | Jefferies | Matthew Taylor | → $75 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | -11.36% | Morgan Stanley | Drew Ranieri | $62 → $66 | Maintains | Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | 0.73% | Piper Sandler | Matt O'Brien | $80 → $75 | Maintains | Overweight | Get Alert |
| 07/20/2022 | Buy Now | -4.65% | Truist Securities | Richard Newitter | $76 → $71 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | -16.73% | Morgan Stanley | Drew Ranieri | $68 → $62 | Maintains | Equal-Weight | Get Alert |
| 05/12/2022 | Buy Now | -8.68% | Morgan Stanley | Drew Ranieri | $74 → $68 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | Buy Now | -1.96% | RBC Capital | Shagun Singh | $78 → $73 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | -5.99% | Wells Fargo | Larry Biegelsen | $80 → $70 | Maintains | Overweight | Get Alert |
| 05/11/2022 | Buy Now | -4.65% | Needham | David Saxon | $76 → $71 | Maintains | Buy | Get Alert |
| 03/28/2022 | Buy Now | 7.44% | Wells Fargo | Larry Biegelsen | → $80 | Initiates | → Overweight | Get Alert |
| 02/22/2022 | Buy Now | -0.62% | Morgan Stanley | Drew Ranieri | $82 → $74 | Maintains | Equal-Weight | Get Alert |
| 02/18/2022 | Buy Now | 22.21% | Credit Suisse | Matt Miksic | $95 → $91 | Maintains | Outperform | Get Alert |
| 02/18/2022 | Buy Now | 2.07% | Needham | David Saxon | $92 → $76 | Maintains | Buy | Get Alert |
| 01/07/2022 | Buy Now | 10.13% | Morgan Stanley | David Lewis | $80 → $82 | Maintains | Equal-Weight | Get Alert |
| 01/04/2022 | Buy Now | 18.18% | Piper Sandler | Matt O'Brien | $80 → $88 | Upgrade | Neutral → Overweight | Get Alert |
| 12/13/2021 | Buy Now | 7.44% | B of A Securities | Craig Bijou | — | Upgrade | Underperform → Buy | Get Alert |
| 08/05/2021 | Buy Now | 20.87% | Canaccord Genuity | Kyle Rose | — | Maintains | Buy | Get Alert |
| 08/05/2021 | Buy Now | 24.9% | Citigroup | Matthew Henriksson | — | Maintains | Buy | Get Alert |
| 08/05/2021 | Buy Now | 7.44% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
| 08/05/2021 | Buy Now | 22.21% | Credit Suisse | Matt Miksic | — | Maintains | Outperform | Get Alert |
| 08/05/2021 | Buy Now | 28.93% | SVB Leerink | Richard Newitter | — | Maintains | Outperform | Get Alert |
| 08/05/2021 | Buy Now | 23.56% | Needham | David Saxon | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Globus Medical (GMED) stock?
The latest price target for Globus Medical (NYSE:GMED) was reported by Truist Securities on July 16, 2024. The analyst firm set a price target for $78.00 expecting GMED to rise to within 12 months (a possible 4.75% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Globus Medical (GMED)?
The latest analyst rating for Globus Medical (NYSE:GMED) was provided by Truist Securities, and Globus Medical maintained their hold rating.
When was the last upgrade for Globus Medical (GMED)?
The last upgrade for Globus Medical Inc happened on May 20, 2024 when Piper Sandler raised their price target to $80. Piper Sandler previously had a neutral for Globus Medical Inc.
When was the last downgrade for Globus Medical (GMED)?
The last downgrade for Globus Medical Inc happened on February 13, 2023 when B of A Securities changed their price target from $83 to $63 for Globus Medical Inc.
When is the next analyst rating going to be posted or updated for Globus Medical (GMED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globus Medical was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Globus Medical (GMED) correct?
While ratings are subjective and will change, the latest Globus Medical (GMED) rating was a maintained with a price target of $63.00 to $78.00. The current price Globus Medical (GMED) is trading at is $74.46, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.